TNFRSF8 and Hodgkins lymphoma: According to a Phase I study, 7 patients with r/r HL were treated with anti-CD30 CAR-T cells, 1 case achieved CR for more than 2.5 years, 1 case sustained CR for almost 2 years, and 3 cases had transient stable disease (SD).